Blog

Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM

Photo of Myriam Chalabi from eurekalert.org

Jun 7, 2024, 14:08

Mark Lewis: Myriam Chalabi reporting the NICHE-2 trial in NEJM

Mark Lewis shared on X: .

“TLC: don’t go chasing waterfalls

Myriam Chalabi reporting the NICHE-2 trial with 95% of locally advanced, mismatch repair-deficient colon cancer responding (pathologically!) to neoadjuvant immunotherapy in NEJM.”

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.

cancer Colon cancer Gastrointestinal Oncology at Intermountain Healthcare in Utah mismatch repair-deficient colon cancer Myriam Chalabi NEJM neoadjuvant immunotherapy NICHE-2 trial OncoDaily Oncology

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25